公开(公告)号：US20240261292A1

公开(公告)日：2024-08-08

申请号：US18560233

申请日：2022-05-09

申请人： Janssen Pharmaceutica NV

发明人： Nikki Daskalakis ,  Christina Diane Guttke ,  Min Chul Kwon ,  Lucille Angela Ferrante ,  Kathryn Elizabeth Packman ,  Eva Christine Pietsch ,  Ulrike Philippar ,  Tinne Ann J. Verhulst ,  Sumia Ali-Ahmed ,  Balpreet Bhogal ,  Yu Sun ,  Wei Cai ,  Xuedong Dai ,  Olivier Alexis Georges Querolle ,  Johannes Wilhelmus J. Thuring ,  Yingtao Liu ,  Lianzhu Liu ,  Yanping Xu ,  Liqiang Fu ,  Ming Li ,  Lichao Fang ,  Xiangjun Deng ,  Alicia Tee Fuay Ng ,  Nicolas Freddy J. Darville ,  Vineet Pande

IPC分类号： A61K31/53 ,  A61K31/4725 ,  A61K31/553 ,  A61K31/704 ,  A61K31/706 ,  A61P35/00

CPC分类号： A61K31/53 ,  A61K31/4725 ,  A61K31/553 ,  A61K31/704 ,  A61K31/706 ,  A61P35/00

摘要： Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:




wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.